COVID 'Cicada' Variant (BA.3.2 & XEC.1.1) Spreads in US, Globally; Immune Evasion Concerns Rise

The BA.3.2 variant, also known as 'Cicada,' and its sublineage XEC.1.1 are drawing increased attention from health officials worldwide due to their potential for immune evasion. First identified in late 2024, BA.3.2 has now been detected in numerous countries and a growing number of U.S. states. The variant's high number of mutations, particularly in the spike protein, is prompting concerns about reduced vaccine effectiveness and increased transmissibility, although data on severity is still being collected. Wastewater monitoring and patient testing are being used to track its spread. The variant was recently detected in a traveler at San Francisco International Airport (SFO), marking its first confirmed presence in the country. Symptoms reported are consistent with previous COVID-19 strains. Health officials urge continued vigilance as the variant gains traction globally, particularly for vulnerable populations with chronic health conditions. ## Latest Update The BA.3.2 variant has now been identified in 29 U.S. states through patient testing and wastewater monitoring. While there is no evidence yet of increased clinical severity, the variant's potential for rapid spread and immune evasion presents a significant public health challenge. ## Timeline * **November 22, 2024:** BA.3.2 first identified in a respiratory sample collected in South Africa. * **June 2025:** First confirmed detection of BA.3.2 in the U.S. * **November 2025 - January 2026:** Significant rise of BA.3.2 in Europe. * **February 2026:** BA.3.2 detected in 25 U.S. states and 23 countries. * **March 2026:** XEC.1.1 detected in a traveler at San Francisco International Airport (SFO). * **March 2026:** BA.3.2 identified in 29 U.S. states through patient testing and wastewater monitoring. ## What to Watch * **Severity Data:** Monitor emerging data on the clinical severity of BA.3.2 and XEC.1.1 infections, particularly in vulnerable populations. * **Dominant Strain:** Track the growth rate of BA.3.2 and XEC.1.1 to determine if it becomes the dominant strain globally. * **Vaccine Effectiveness:** Pay attention to studies assessing the effectiveness of current vaccines against BA.3.2 and XEC.1.1.